Vosoritide (BMN 111) acetate is a natriuretic peptide receptor 2 (NPR2) agonist that acts on the proliferation and differentiation of chondrocytes to promote bone growth.In Vitro:Vosoritide (0.1 μM; 1 h) acetate decreases NPR2 phosphorylation in chondrocytes[2].
Vosoritide (0.1 μM; 6 d) acetate improves chondrocyte differentiation and increases the proliferative growth plate area of cultured Fgfr3Y367C/+ femurs[2].
Vosoritide (10 μM; overnight) acetate reduces ERK1/2 activation in ACH growth-plate chondrocytes.In Vivo:Vosoritide (subcutaneous injection; 800 μg/kg; once daily; 20 d) acetate treatment leads to improvement in skeletal parameters in Fgfr3 gain-of-function mutation mouse.